Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 8/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.32 |
| ▸ | CTSE | P14091 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 5/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | SPR | P35270 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | HTR1B | P28222 | 1/20 | 0.32 |
| ▸ | MPO | P05164 | 1/20 | 0.32 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3764889 | 0.77 | CAPN1 (0.33) | RENHTR1DHTR1B | |
| SCHEMBL4531230 | 0.76 | CYP3A4 (0.30) | — | |
| SCHEMBL3769448 | 0.75 | REN (0.41) | REN | |
| SCHEMBL4755820 | 0.74 | REN (0.35) | RENSPRHTR1DHTR1B | |
| SCHEMBL5050472 | 0.73 | HTR1D (0.35) | CTSDSPRHTR1DHTR1B | |
| SCHEMBL1047567 | 0.73 | HTR1D (0.39) | SPRHTR1DHTR1B | |
| SCHEMBL1049891 | 0.72 | MTNR1A (0.35) | SPRMPO | |
| SCHEMBL3772837 | 0.72 | CAPN1 (0.34) | HTR1DHTR1B | |
| SCHEMBL4754633 | 0.72 | CTSD (0.33) | RENCTSDHTR1DHTR1B | |
| SCHEMBL3769416 | 0.70 | HTR1D (0.38) | RENSPRHTR1DHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851634-B2 | 5-amino 4-hydroxy-7-(1H-indolmethyl)-8-methylnonamide derivatives as renin inhibitors for the treatment of hypertension | NOVARTIS AG (CH) | 2010-12-14 | — | — | US | disclosed |
| EP-1717226-B1 | 2,7-SUBSTITUTED 5-AMINO-4-HYDROXY-8-(1H-INDOL-5-YL)-OCTAN AMIDE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | SPEEDEL EXPERIMENTA AG (CH) | 2009-01-21 | — | — | EP | disclosed |
| US-20080280895-A1 | 5-Amino-4-Hydroxy-7-(1H-Indolmethyl)-8-Methylnonamide Derivatives as Renin Inhibitors for the Treatment of Hypertension | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | disclosed |
| EP-1724259-A1 | 2,7-SUBSTITUTED 5-AMINO-4-HYDROXY-8-(1H-INDAZOL-5-YL)-OCTAN AMIDE DERIVATIVES AND RELATED COMPOUNDS AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | Speedel Experimenta AG (CH) | 2006-11-22 | — | — | EP | disclosed |
| EP-1717226-A1 | 2,7-SUBSTITUTED 5-AMINO-4-HYDROXY-8-(1H-INDOL-5-YL)-OCTAN AMIDE DERIVATIVES AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | Speedel Experimenta AG (CH) | 2006-11-02 | — | — | EP | disclosed |
| EP-1712548-A2 | 5-AMINO-4-HYDROXY-7-(PYRIDINYLMETHYL)-ALKANAMIDE DERIVATIVES AND RELATED COMPOUNDS AS RENIN INHIBITORS FOR THE TREATMENT OF HYPERTENSION | Speedel Experimenta AG (CH) | 2006-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280895-A1 | 5-Amino-4-Hydroxy-7-(1H-Indolmethyl)-8-Methylnonamide Derivatives as Renin Inhibitors for the Treatment of Hypertension | REN, AGTR1, AGTR2 | REN 1/4885CTSD 1360/4885CTSE 1402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.